Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Trulicity ® (dulaglutide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Can I use Trulicity® (dulaglutide) in patients with a history of Pancreatitis
Dulaglutide has not been studied in patients with a history of pancreatitis. Consider other antihyperglycemic therapies in patients with a history of pancreatitis.
What should I do if a patient shows signs of pancreatitis ?
- Discontinue dulaglutide therapy if you suspect pancreatitis
- Do not restart dulaglutide therapy if pancreatitis is confirmed
- Inform the patients about the characteristic symptoms of acute pancreatitis.
Elevations in pancreatic enzymes alone, without other signs of acute pancreatitis, are not predictive of acute pancreatitis.1
After initiation of dulaglutide, observe patients carefully for signs and symptoms of pancreatitis, including persistent severe abdominal pain.2
1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 05 October 2020